CARTITUDE-4 Highlights: Cilta-Cel vs Standard of Care in R/R MM

Opinion
Video

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ciltacabtagene autoleucel (cilta-cel) compared with standard treatment options in relapsed/refractory multiple myeloma (R/R MM) patients who received 1 to 3 prior lines of therapy.

Current Time 0:00
Duration 5:52
Loaded: 0%
Stream Type LIVE
Remaining Time 5:52
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay up to date on practice-changing data in community practice.

    Subscribe Now!
    Recent Videos
    3 experts are featured in this series.
    COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
    3 experts are featured in this series.
    Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
    Clinical Impact of COCOON: Advancing Dermatologic AE Management
    Clinical Impact of COCOON: Advancing Dermatologic AE Management
    Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
    Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
    Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
    Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
    Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
    Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
    1 expert is featured in this series.
    Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
    3 experts are featured in this series.
    Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
    3 experts are featured in this series.
    Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
    Related Content
    Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

    Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

    Jason M. Broderick
    April 17th 2025
    Article

    Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its approval of the treatment last year.

    Read More

    Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

    Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

    Binod Dhakal, MD, MS;Jordyn Sava
    June 14th 2024
    Podcast

    In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

    Listen

    Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

    Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

    Tony Berberabe, MPH
    April 11th 2025
    Article

    A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

    Read More

    Advancing Myeloma Treatment With Blood-Based MRD Testing

    Advancing Myeloma Treatment With Blood-Based MRD Testing

    Jordyn Sava;Ben Derman, MD
    February 15th 2024
    Podcast

    In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

    Listen

    Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

    Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

    Jordyn Sava
    April 10th 2025
    Article

    Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

    Read More

    Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

    Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

    Targeted Oncology Staff
    April 8th 2025
    Article

    During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

    Read More